49 related articles for article (PubMed ID: 9820111)
1. [Clinical significance of glucose-dependent insulinotropic polypeptide (GIP)].
Bartos V
Vnitr Lek; 1998 Apr; 44(4):240-4. PubMed ID: 9820111
[TBL] [Abstract][Full Text] [Related]
2. Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide.
Meier JJ; Nauck MA
Best Pract Res Clin Endocrinol Metab; 2004 Dec; 18(4):587-606. PubMed ID: 15533777
[TBL] [Abstract][Full Text] [Related]
3. Extrapancreatic effects of GIP and GLP-1.
Vella A; Rizza RA
Horm Metab Res; 2004; 36(11-12):830-6. PubMed ID: 15655715
[TBL] [Abstract][Full Text] [Related]
4. Glucose-dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity-associated disorders.
Paschetta E; Hvalryg M; Musso G
Obes Rev; 2011 Oct; 12(10):813-28. PubMed ID: 21815989
[TBL] [Abstract][Full Text] [Related]
5. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP).
McIntosh CH; Widenmaier S; Kim SJ
Vitam Horm; 2009; 80():409-71. PubMed ID: 19251046
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
Irwin N; Clarke GC; Green BD; Greer B; Harriott P; Gault VA; O'Harte FP; Flatt PR
Biochem Pharmacol; 2006 Sep; 72(6):719-28. PubMed ID: 16859646
[TBL] [Abstract][Full Text] [Related]
7. Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16).
Irwin N; Green BD; Parker JC; Gault VA; O'Harte FP; Flatt PR
Regul Pept; 2006 Jul; 135(1-2):45-53. PubMed ID: 16675042
[TBL] [Abstract][Full Text] [Related]
8. The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility.
Edholm T; Cejvan K; Abdel-Halim SM; Efendic S; Schmidt PT; Hellström PM
Neurogastroenterol Motil; 2009 Mar; 21(3):313-21. PubMed ID: 19126188
[TBL] [Abstract][Full Text] [Related]
9. cDNA array reveals increased expression of glucose-dependent insulinotropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drug-induced adverse metabolic effects.
Sondhi S; Castellano JM; Chong VZ; Rogoza RM; Skoblenick KJ; Dyck BA; Gabriele J; Thomas N; Ki K; Pristupa ZB; Singh AN; MacCrimmon D; Voruganti P; Foster J; Mishra RK
Pharmacogenomics J; 2006; 6(2):131-40. PubMed ID: 16402076
[TBL] [Abstract][Full Text] [Related]
10. GIP or not GIP? That is the question.
Kieffer TJ
Trends Pharmacol Sci; 2003 Mar; 24(3):110-2. PubMed ID: 12628351
[TBL] [Abstract][Full Text] [Related]
11. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.
Ranganath LR
J Clin Pathol; 2008 Apr; 61(4):401-9. PubMed ID: 18375745
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
13. Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets.
Cassidy RS; Irwin N; Flatt PR
Biol Chem; 2008 Feb; 389(2):189-93. PubMed ID: 18163884
[TBL] [Abstract][Full Text] [Related]
14. On the physiology of GIP and GLP-1.
Holst JJ
Horm Metab Res; 2004; 36(11-12):747-54. PubMed ID: 15655703
[TBL] [Abstract][Full Text] [Related]
15. Glucose-dependent insulinotropic peptide: differential effects on hepatic artery vs. portal vein endothelial cells.
Ding KH; Zhong Q; Xu J; Isales CM
Am J Physiol Endocrinol Metab; 2004 May; 286(5):E773-9. PubMed ID: 14709420
[TBL] [Abstract][Full Text] [Related]
16. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
Svendsen PF; Nilas L; Madsbad S; Holst JJ
Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
[TBL] [Abstract][Full Text] [Related]
17. NMR structure of the glucose-dependent insulinotropic polypeptide fragment, GIP(1-30)amide.
Alaña I; Hewage CM; Malthouse JP; Parker JC; Gault VA; O'Harte FP
Biochem Biophys Res Commun; 2004 Dec; 325(1):281-6. PubMed ID: 15522230
[TBL] [Abstract][Full Text] [Related]
18. Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.
Kerr BD; Irwin N; O'Harte FP; Bailey CJ; Flatt PR; Gault VA
Biochem Pharmacol; 2009 Oct; 78(8):1008-16. PubMed ID: 19523458
[TBL] [Abstract][Full Text] [Related]
19. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans.
Meier JJ; Goetze O; Anstipp J; Hagemann D; Holst JJ; Schmidt WE; Gallwitz B; Nauck MA
Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E621-5. PubMed ID: 14678954
[TBL] [Abstract][Full Text] [Related]
20. The insulinotropic region of gastric inhibitory polypeptide; fragment analysis suggests the bioactive site lies between residues 19 and 30.
Morrow GW; Kieffer TJ; McIntosh CH; MacGillivray RT; Brown JC; St Pierre S; Pederson RA
Can J Physiol Pharmacol; 1996 Jan; 74(1):65-72. PubMed ID: 8963953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
